CYduct Diagnostics Positions Intraductal Platform to Address Multi-Billion-Dollar Gap in Breast Cancer Screening

Ductal-origin approach targets two underserved segments, women with dense breasts and those at elevated risk, where conventional imaging may faces limitations.

WESTPORT, CT, UNITED STATES, August 11, 2026 /EINPresswire.com/ -- CYduct Diagnostics, Inc. (OTC Pink: CYDX) (“CYduct” or the “Company”) today highlighted the market opportunity for its intraductal breast health platform and the Company’s strategy to address a persistent gap in the current standard of care for breast cancer detection and risk assessment.

Mammography, ultrasound and MRI remain central to breast cancer screening and diagnostic evaluation. However, breast density can reduce the sensitivity of mammography and complicate the detection of abnormalities, creating an important unmet need among the tens of millions of women in the United States with dense breast tissue. Women at elevated risk for breast cancer may also require more intensive surveillance and additional diagnostic tools.

CYduct believes these populations represent a significant and underserved segment of the breast health market and an area where its ductal-origin technology platform may offer a differentiated approach. CYduct’s strategy is grounded in the biology of breast cancer, with the majority of breast cancers arising from epithelial cells within the mammary ductal system. The Company’s technology portfolio including its HALO breast fluid collection system and MammoView ductal visualization technology is designed to access the ductal environment directly, providing a pathway to collect, evaluate and monitor biological information at the site where many breast cancers originate.

Unlike conventional imaging, CYduct’s intraductal approach is not dependent on breast density for access to the mammary ducts. The Company believes this distinction could position its platform as a complementary tool within the broader breast health ecosystem rather than as a replacement for established imaging modalities.

Strategic Significance
● Differentiated market position: CYduct’s intraductal approach is designed to address populations including women with dense breasts and women at elevated risk where additional tools beyond conventional mammography may be particularly valuable.
● Platform, not a single product: The Company’s technology portfolio spans breast fluid collection, risk assessment, monitoring and direct ductal visualization, supporting a multi-product development strategy and multiple potential commercial pathways.
● Large addressable population: Women with dense breast tissue and those at elevated risk represent a substantial segment of the broader breast health market, supported by increasing awareness of breast density and expanded requirements for breast-density notification.

“The breast health market has historically been built around imaging, yet imaging alone does not address every clinical need particularly for women with dense breast tissue and those at elevated risk,” said Dom Gatto, Chief Executive Officer of CYduct Diagnostics. “CYduct’s strategy is to complement existing screening by going directly to the mammary ducts, where most breast cancers originate, and accessing biological information that conventional imaging cannot provide on its own. We believe this differentiated, ductal-origin approach has the potential to create meaningful value for patients, clinicians and our shareholders as we continue to advance our intraductal platform.”

Additional information on its line of products will be available on the Company's website at: www.CYductDX.com.

FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION
This press release contains forward-looking statements, including statements regarding Cyduct’s plans, expectations, beliefs, objectives and future performance. Such statements may be identified by words such as “may,” “could,” “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “potential” and similar expressions. Forward-looking statements are based on management’s current assumptions, estimates and information and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. Accordingly, such statements are not guarantees of future performance, and readers should not place undue reliance on them. Additional risks are described in the Company’s Annual Report and other filings with OTC Markets Group, available at www.otcmarkets.com. All forward-looking statements speak only as of the date of this release, and Cyduct undertakes no obligation to update or revise them except as required by law.

CONTACT:
CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYduct Diagnostics, Inc.

Dom Gatto
email us here
CYduct Diagnostics, Inc.